Bank of America
ATRA icon

Bank of America’s Atara Biotherapeutics ATRA Stock Holding History

Bank of America’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,387
Closed -$188K – 5778
2025
Q4 		$188K Buy
10,387
+4,542
+78% +$67.8K ﹤0.01% 5372
2025
Q3 		$83.8K Sell
5,845
-1,843
-24% -$21.2K ﹤0.01% 6671
2025
Q2 		$59.4K Sell
7,688
-179,609
-96% -$1.31M ﹤0.01% 6751
2025
Q1 		$1.11M Sell
187,297
-17,873
-9% -$156K ﹤0.01% 5146
2024
Q4 		$2.73M Buy
205,170
+1,543
+0.8% +$16.3K ﹤0.01% 4173
2024
Q3 		$1.66M Buy
203,627
+17,616
+9% +$151K ﹤0.01% 4701
2024
Q2 		$1.58M Sell
186,011
-77,212
-29% -$1.16M ﹤0.01% 4604
2024
Q1 		$4.57M Buy
263,223
+255,658
+3,379% +$4.54M ﹤0.01% 3699
2023
Q4 		$96.8K Buy
7,565
+3,641
+93% +$84.9K ﹤0.01% 6386
2023
Q3 		$145K Buy
3,924
+671
+21% +$29.9K ﹤0.01% 6080
2023
Q2 		$131K Sell
3,253
-45,319
-93% -$2.56M ﹤0.01% 6088
2023
Q1 		$3.52M Buy
48,572
+33,513
+223% +$3.25M ﹤0.01% 3852
2022
Q4 		$1.23M Sell
15,059
-4,286
-22% -$447K ﹤0.01% 4665
2022
Q3 		$1.83M Buy
19,345
+5,487
+40% +$616K ﹤0.01% 4365
2022
Q2 		$2.7M Buy
13,858
+6,403
+86% +$1.05M ﹤0.01% 4031
2022
Q1 		$1.73M Buy
7,455
+2,500
+50% +$796K ﹤0.01% 4727
2021
Q4 		$1.95M Buy
4,955
+2,509
+103% +$1.06M ﹤0.01% 4581
2021
Q3 		$1.09M Buy
2,446
+875
+56% +$313K ﹤0.01% 4974
2021
Q2 		$611K Sell
1,571
-3,085
-66% -$1.1M ﹤0.01% 5271
2021
Q1 		$1.67M Buy
4,656
+3,738
+407% +$1.65M ﹤0.01% 4408
2020
Q4 		$450K Sell
918
-2,931
-76% -$1.35M ﹤0.01% 5080
2020
Q3 		$1.25M Buy
3,849
+2,675
+228% +$911K ﹤0.01% 4029
2020
Q2 		$428K Sell
1,174
-6,044
-84% -$1.53M ﹤0.01% 4728
2020
Q1 		$1.54M Buy
7,218
+3,523
+95% +$1.12M ﹤0.01% 3685
2019
Q4 		$1.52M Sell
3,695
-1,475
-29% -$509K ﹤0.01% 4208
2019
Q3 		$1.82M Sell
5,170
-4,910
-49% -$1.83M ﹤0.01% 4131
2019
Q2 		$5.07M Buy
10,080
+2,546
+34% +$1.8M ﹤0.01% 3225
2019
Q1 		$7.49M Buy
7,534
+3,703
+97% +$3.44M ﹤0.01% 2762
2018
Q4 		$3.33M Sell
3,831
-1,834
-32% -$1.7M ﹤0.01% 3399
2018
Q3 		$5.86M Sell
5,665
-2,303
-29% -$2.25M ﹤0.01% 3036
2018
Q2 		$7.32M Buy
7,968
+2,952
+59% +$3.17M ﹤0.01% 2765
2018
Q1 		$4.89M Buy
5,016
+985
+24% +$898K ﹤0.01% 3103
2017
Q4 		$1.82M Sell
4,031
-3,984
-50% -$1.47M ﹤0.01% 4041
2017
Q3 		$3.31M Buy
8,015
+2,990
+60% +$1.13M ﹤0.01% 3557
2017
Q2 		$1.76M Sell
5,025
-201
-4% -$77.4K ﹤0.01% 3991
2017
Q1 		$2.68M Buy
5,226
+507
+11% +$210K ﹤0.01% 3604
2016
Q4 		$1.68M Buy
4,719
+1,781
+61% +$754K ﹤0.01% 3915
2016
Q3 		$1.57M Sell
2,938
-99
-3% -$53.8K ﹤0.01% 3826
2016
Q2 		$1.71M Sell
3,037
-24
-0.8% -$11.5K ﹤0.01% 3759
2016
Q1 		$1.46M Buy
3,061
+22
+0.7% +$9.9K ﹤0.01% 3834
2015
Q4 		$2.01M Buy
3,039
+1,142
+60% +$864K ﹤0.01% 3796
2015
Q3 		$1.49M Buy
1,897
+1,826
+2,572% +$2.23M ﹤0.01% 4024
2015
Q2 		$94K Buy
71
+70
+7,000% +$80.3K ﹤0.01% 5621
2015
Q1 		$1K Buy
+1
New +$661 ﹤0.01% 6776

Other funds holding ATRA

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America's ATRA Position: Q1 2026 in Review

Bank of America sold out of Atara Biotherapeutics (ATRA) in Q1 2026, closing a stake of 10,387 shares — an estimated $188K sold.

Bank of America first reported a position in ATRA in Q1 2015 and held it in 44 quarters. The position peaked at $7.49M in Q1 2019. 33 funds tracked by Wall St. Rank hold ATRA as of Q1 2026.

  • Bank of America reported no remaining Atara Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 10,387 Atara Biotherapeutics shares in Q1 2026, an estimated $188K.
  • Bank of America first reported a position in Atara Biotherapeutics in Q1 2015 and held it in 44 quarters.
  • Bank of America's Atara Biotherapeutics position peaked at $7.49M in Q1 2019.
  • 33 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.